Download PDF
Semin intervent Radiol 2018; 35(04): 350-355
DOI: 10.1055/s-0038-1673423
Trainee Corner
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Liver Tumors with Transarterial Chemoembolization

Natalie Poliektov
1   Department of Radiology, University of Colorado College of Medicine, Aurora, Colorado
,
D. Thor Johnson
1   Department of Radiology, University of Colorado College of Medicine, Aurora, Colorado
› Author Affiliations
Further Information

Publication History

Publication Date:
05 November 2018 (online)

Also available at
    Permissions and Reprints

Liver cancer is the fifth most common cancer among men and the ninth most common cancer among women worldwide, and is the second most common cause of cancer mortality for men and women combined.[1] Moreover, liver cancer death rates currently have the most rapid rise of all cancer deaths among both sexes worldwide.[2] Chemotherapy treatment options have also been limited by general insensitivity to systemic chemotherapy.[3]

Transcatheter arterial embolization (TAE) was first reported in 1974 as a novel treatment for liver tumors.[4] In the early 1980s, utilization of lipiodol allowed inclusion of chemotherapy and the practice of transarterial chemoembolization (TACE) became widespread.[5] TACE combines conventional TAE with regional chemotherapy to selectively induce ischemia and chemotherapy effects within the tumor while minimizing damage to the untreated liver. It is currently indicated as the first-line treatment for patients with unresectable intermediate-stage hepatocellular carcinoma (HCC), for down staging patients to Milan's criteria for orthotopic liver transplant, as a bridging therapy to prevent transplant list drop off, and as a palliative treatment.[6] [7] [8]

While different methods of embolotherapy are commonly used in the treatment of liver tumors, management is variable across medical centers. This article aims to provide insight into the factors the authors consider in their clinical practice when determining appropriate treatment for a patient.

 

  • References

  • 1 Ferlay J, Soerjomataram I, Dikshit R. , et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (05) E359-E386
    CrossrefPubMedGoogle Scholar
  • 2 Ryerson AB, Eheman CR, Altekruse SF. , et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016; 122 (09) 1312-1337
    CrossrefPubMedGoogle Scholar
  • 3 Marin JJG, Castano B, Martinez-Becerra P. , et al. Chemotherapy in the treatment of primary liver tumours. Cancer Ther 2008; 6: 711-728
    PubMedGoogle Scholar
  • 4 Doyon D, Mouzon A, Jourde AM, Regensberg C, Frileux C. [Hepatic, arterial embolization in patients with malignant liver tumours (author's transl)]. Ann Radiol (Paris) 1974; 17 (06) 593-603
    PubMedGoogle Scholar
  • 5 Nakakuma K, Tashiro S, Hiraoka T. , et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 1983; 52 (12) 2193-2200
    CrossrefPubMedGoogle Scholar
  • 6 Bruix J, Sherman M. ; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (03) 1020-1022
    CrossrefPubMedGoogle Scholar
  • 7 European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (04) 908-943
    CrossrefPubMedGoogle Scholar
  • 8 Rammohan A, Sathyanesan J, Ramaswami S. , et al. Embolization of liver tumors: past, present and future. World J Radiol 2012; 4 (09) 405-412
    CrossrefPubMedGoogle Scholar
  • 9 Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009; 10 (05) 425-434
    CrossrefPubMedGoogle Scholar
  • 10 Garwood ER, Fidelman N, Hoch SE, Kerlan Jr RK, Yao FY. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl 2013; 19 (02) 164-173
    CrossrefPubMedGoogle Scholar
  • 11 Osuga K, Maeda N, Higashihara H. , et al. Current status of embolic agents for liver tumor embolization. Int J Clin Oncol 2012; 17 (04) 306-315
    CrossrefPubMedGoogle Scholar
  • 12 Speakman TJ. Internal occlusion of a carotid-cavernous fistula. J Neurosurg 1964; 21: 303-305
    CrossrefPubMedGoogle Scholar
  • 13 Tadavarthy SM, Moller JH, Amplatz K. Polyvinyl alcohol (Ivalon)--a new embolic material. Am J Roentgenol Radium Ther Nucl Med 1975; 125 (03) 609-616
    CrossrefPubMedGoogle Scholar
  • 14 Miyayama S, Matsui O, Yamashiro M. , et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007; 18 (03) 365-376
    CrossrefPubMedGoogle Scholar
  • 15 Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989; 170 (3, Pt 1): 783-786
    CrossrefPubMedGoogle Scholar
  • 16 Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol 2013; 30 (01) 3-11
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. Jpn J Clin Oncol 2012; 42 (04) 247-255
    CrossrefPubMedGoogle Scholar
  • 18 Marelli L, Stigliano R, Triantos C. , et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30 (01) 6-25
    CrossrefPubMedGoogle Scholar
  • 19 Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30 (05) 969-977
    PubMedGoogle Scholar